脐带间充质干细胞移植治疗终末期肝硬化的疗效及安全性

Effect and safety of umbilical cord mesenchymal stem cells transplantation on end-stage liver cirrhosis

背景:骨髓间充质干细胞移植已应用于治疗终末期肝病并取得一定疗效。目的:观察脐带间充质干细胞治疗终末期肝硬化患者的疗效及安全性。方法:无菌条件下分离培养脐带间充质干细胞,选择60例肝硬化患者,在内科治疗基础上经肝动脉插管进行脐带间充质干细胞移植。结果与结论:移植2,4,8,12周后,患者血清白蛋白、前白蛋白水平逐渐升高(P<0.05),总胆红素、凝血酶原时间明显低于治疗前水平(P<0.05)。移植后患者乏力、腹胀、纳差明显好转,未发生与移植相关的严重并发症。说明脐带间充质干细胞治疗终末期肝硬化安全有效,能改善患者的肝功能、凝血功能及临床症状。

BACKGROUND： Bone mesenchymal stem cells （BMSCs） transplantation has been used for end-stage liver cirrhosis, and obtained some results. OBJECTIVE： To observe the effect and safety of umbilical cord mesenchymal stem cells （UCMSCs） transplantation on end-stage hepatic cirrhosis. METHODS： UCMSCs were isolated under sterile conditions. Sixty cases of liver cirrhosis received basic medication and UCMSCs transplantation by way of hepatic artery. RESULTS AND CONCLUSION： After UCMSCs treatment, the level of albumin, prealbumin and fibrinogen were significantly increased （P 0.05）, and the levels of total bilirubin and prothrombin time were obviously reduced （P 0.05）. The symptoms such as fatigue, abdominal distension, anorexia relieved after treatment. UCMSCs transplantation for end-stage liver cirrhosis is safe and effective, and it can improve patients＇ liver function, blood clotting and relieve clinical symptoms.